logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9890202 B1

PDFFull Text
Date of Patent:
Feb. 13, 2018

Filed:

Jul. 19, 2011

Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases

Applicants:

Yechiel Shai, Yahud, IL;

Avner Fink, Rehovot, IL;

Eliran-moshe Reuven, Rehovot, IL;

Liraz Shmuel-galia, Rehovot, IL;

Inventors:

Yechiel Shai, Yahud, IL;

Avner Fink, Rehovot, IL;

Eliran-Moshe Reuven, Rehovot, IL;

Liraz Shmuel-Galia, Rehovot, IL;

Assignee:

Yeda Research and Development Co. Ltd., Rehovot, IL;

Attorney:
Primary Examiner:

Hasan Ahmed

Assistant Examiner:

Thea D'Ambrosio

Int. Cl.
CPC ...
A61K 38/16 (2006.01); A61K 38/10 (2006.01); A61K 38/00 (2006.01); A61K 38/04 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 14/705 (2006.01); C07K 7/08 (2006.01); C07K 4/00 (2006.01); C07K 14/00 (2006.01); A61K 38/03 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 38/03 (2013.01); A61K 38/04 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); C07K 4/00 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); A61K 38/00 (2013.01);
Abstract

Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.

Find Patent Forward Citations

Loading…